

GENERAL SESSION 1 | WEDNESDAY, DECEMBER 6 | 9:00AM-12:00PM CT

GS01-01 Biomarker Results in High-risk Estrogen Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative Primary Breast Cancer Following Neoadjuvant Chemotherapy ± Nivolumab: an Exploratory Analysis of CheckMate 7FL. Sherene Loi (1) Giuseppe Curigliano (2) Roberto Salgado (3) Roberto Iván Romero Díaz (4) Suzette Delaloge (5) Carlos Ignacio Rojas García (6) Marleen Kok (7) Cristina Saura (8) Nadia Harbeck (9) Elizabeth Mittendorf (10) Denise Yardley (11) Lajos pusztai (12) Alberto Suárez Zaizar (13) Andrei Ungureanu (14) Felipe Ades (15) Rajalakshmi Chandra (15) Raheel Nathani (15) Misena Pacius (15) Thomas Spires (15) Jenny Wu (16) Heather McArthur (17)
(1) Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia;(2) European Institute of Oncology and University of Milano, Milano, Lombardia, Italy;(3) GZA-ZNA-Hospitals, Antwerp, Belgium; Peter Mac Callum Cancer Centre, Belgium;(4) Consultorio de Oncólogo Médico, Mexico;(5) Institut Gustave Roussy, Villejuif, Ile-de-France, France;(6) Bradford Hill Investigación Clínica, Santiago, Región Metropolitana, Chile;(7) Netherlands Cancer Institute, Netherlands;(8) Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University Hospital, Barcelona, Catalonia, Spain;(9) University of Munich, Germany;(10) Dana Farber Cancer Institute, Boston, MA, United States;(11) Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN, United States;(12) Yale School of Medicine, Cancer Center, New Haven, CT, United States;(13) CENEIT Oncológicos, Mexico;(14) Radiotherapy Center CLUJ S.R.L., Romania;(15) Bristol Myers Squibb, Princeton, NJ, United States;(16) Bristol Myers Squibb;(17) UT Southwestern, Dallas, TX, United States.

GS01-02 Phase 3 study of neoadjuvant pembrolizumab or placebo plus chemotherapy, followed by adjuvant pembrolizumab or placebo plus endocrine therapy for early-stage high-risk ER+/HER2– breast cancer: KEYNOTE-756. Fatima Cardoso (1) Joyce O'Shaughnessy (2) Heather McArthur (3) Peter Schmid (4) Javier Cortés (5) Nadia Harbeck (6) Melinda Telli (7) David Cescon (8) Peter A. Fasching (9) Zhimin Shao (10) Delphine Loirat (11) Yeon Hee Park (12) Manuel Gonzalez Fernandez (13) Gabor Rubovszky (14) Seock-Ah Im (15) Rina Hui (16) Toshimi Takano (17) Fabrice André (18) Hiroyuki Yasojima (19) Zhenzhen Liu (20) Yu Ding (21) Liyi Jia (21) Vassiliki Karantza (22) Konstantinos Tryfonidis (21) Aditya Bardia (23)
(1) Breast Unit, Champalimaud Clinical Center/Champalimaud Foundation, Portugal;(2) Baylor University Medical Center, Texas Oncology, US Oncology, Dallas, TX, United States;(3) UT Southwestern, Dallas, TX, United States;(4) Centre for Experimental Cancer Medicine, Barts Cancer Institute, Queen Mary University London, United Kingdom;(5) International Breast Cancer Center (IBCC), Pangaea Oncology, Quironsalud Group, Madrid and Barcelona, Spain & Faculty of Biomedical and Health Sciences, Department of Medicine, Universidad Europea de Madrid, Spain;(6) University of Munich, Germany;(7) Stanford University School of Medicine, San Francisco, CA, United States;(8) Princess Margaret Cancer Centre/UHN, Toronto, Ontario, Canada;(9) Department of Obstetrics and Gynecology, University Hospital Erlangen, Germany;(10) Department of Breast Surgery, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, China (People's Republic);(11) Institut Curie, Medical Oncology Department and D3i, France;(12) Samsung Medical Center, Republic of Korea;(13) IMAT-Oncomedica, Montería, Colombia;(14) National Institute of Oncology, Hungary;(15) Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Republic of Korea;(16) Crown Princess Mary Cancer Centre, Westmead Hospital, Sydney, NSW, Australia;(17) The Cancer Institute Hospital of JFCR, Koto-ku, Tokyo, Japan;(18) Faculté de Médecine Paris-Sud XI, Gustave Roussy, France;(19) Department of Surgery, Breast Oncology NHO Osaka National Hospital;(20) Henan Breast Cancer Center, Affiliated Cancer Hospital of Zhengzhou

University & Henan Cancer Hospital, Zhengzhou, Henan, China;(21) Merck & Co., Inc., Rahway, NJ, United States;(22) Merck Sharp & Dohme LLC, Rahway, NJ, United States;(23) Massachusetts General Hospital Cancer Center, Boston, MA, United States.

GS01-03 Adding atezolizumab to adjuvant chemotherapy for stage II and III triple-negative breast cancer is unlikely to improve efficacy: interim analysis of the ALEXANDRA/IMpassion030 phase 3 trial..

Michail Ignatiadis (1) Andrew Bailey (2) Heather McArthur (3) Sarra El-Abed (4) Evandro de Azambuja (5) Otto Metzger (6) Steve Chui (7) Max Dieterich (8) Thomas Perretti (9) Guenther Steger (10) Jacek Jassem (11) Soo Chin Lee (12) Michaela Higgins (13) José Zarbá (14) Marcus Schmidt (15) Henry Gomez (16) Angel Guerrero-Zotano (17) Luca Moscetti (18) Joanne Win Yang Chiu (19) Carter DuFrane (20) Vanessa Honvault (21) Rosa Altarcheh (22) Luciana Molinero (23) Andrew Ellingson (2) Elisabetta Munzone (24) Noa Efrat Ben-Baruch (25) Emilio Bajetta (26) Shinji Ohno (27) Seock-Ah Im (28) Gustavo Werutsky (29) Einav Gal-Yam (30) Xavier Gonzalez-Farré (31) Ling-Ming Tseng (32) William Jacot (33) Oleg Gluz (34) Zhimin Shao (35) Yaroslav Shparyk (36) Ivan Sinielnikov (37) Zimina Anastasia (38) Aleksandr Vasiliev (39) Esther Shearer-Kang (7) Eric Winer (40) Diogo Martins-Branco (41) Shona Fielding (2) David Cameron (42) Giuseppe Viale (43) Shigehira Saji (44) Richard Gelber (6) Martine Piccart (1)

(1) Institut Jules Bordet and l'Université Libre de Bruxelles (U.L.B.);(2) Frontier Science Scotland, Kincaig, Kingussie, United Kingdom;(3) UT Southwestern, Dallas, TX, United States;(4) Breast International Group BIG, Belgium;(5) Institut Jules Bordet and l'Université Libre de Bruxelles (U.L.B.), Belgium;(6) Dana-Farber Cancer Institute, Boston, MA, United States;(7) Genentech, Inc., South San Francisco, CA, United States;(8) F. Hoffmann-La Roche Ltd;(9) F. Hoffman-La Roche;(10) Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria, Austria;(11) Medical University of Gdańsk, Poland;(12) National University of Singapore;(13) Cancer Trials Ireland;(14) Medical College of Tucuman;(15) Universität Mainz, Klinik und Poliklinik für Geburtshilfe und Frauengesundheit, Germany;(16) Instituto Nacional de Enfermedades Neoplásicas, INEN, Departamento de Oncología Médica, Peru;(17) Fundación Instituto Valenciano de Oncología (FIVO). GEICAM Spanish Breast Cancer Group., Spain;(18) University Hospital of Modena and Reggio Emilia, Department of Oncology and Hematology, Italy;(19) Queen Mary Hospital, China;(20) Alliance Foundation Trials;(21) Institut Jules Bordet;(22) BIG Against Breast Cancer;(23) Translational Medicine Oncology - Genentech;(24) European Institute of Oncology, IRCCS, Italy;(25) Holy Family Hospital, Israel;(26) Fondazione Policlinico di Monza - Presidente Gruppo I.T.M.O.;(27) Breast Oncology Center, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Japan;(28) Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Republic of Korea;(29) Latin American Cooperative Oncology Group (LACOG), Brazil;(30) Breast Oncology Institute Sheba Medical Center;(31) Intituto Oncológico Dr. Rosell, Hospital General de Catalunya, Catalonia, Spain;(32) Taipei Veterans General Hospital;(33) Institut du Cancer de Montpellier, Université de Montpellier, INSERM U1194, Paris, Montpellier, Languedoc-Roussillon, France;(34) West German Study Group, Moenchengladbach, Germany; Breast Center Niederrhein, Ev. Hospital Bethesda, Moenchengladbach, Germany; University Clinics Cologne, Germany;(35) Fudan University Shanghai Cancer Center;(36) Danylo Halytsky Lviv National Medical University;(37) Volyn Regional Oncology Center, Ukraine;(38) Russian Federation;(39) Nuz "Dkb Oao Rzd", Russian Federation;(40) Yale Cancer Center, New Haven, CT, United States;(41) Université Libre de Bruxelles (U.L.B.), Hôpital Universitaire de Bruxelles (HUB), Institut Jules Bordet, Academic Trials Promoting Team (ATPT), Belgium;(42) The University of Edinburgh, Edinburgh Cancer Research, EDINBURGH, Scotland, United Kingdom;(43) European Institute of Oncology IRCCS, and University of Milan, Italy;(44) Fukushima Medical University, Japan.

GS01-05 Pembrolizumab + Olaparib vs Pembrolizumab + Chemotherapy After Induction With Pembrolizumab + Chemotherapy for Locally Recurrent Inoperable or Metastatic TNBC: Randomized Open-Label Phase 2 KEYLYNK-009 Study. Hope Rugo (1) Mark Robson (2) Seock-Ah Im (3) Florence Dalenc (4) Eduardo Yañez Ruiz (5) Young-Hyuck Im (6) Sergii Kulyk (7) Oleksandr Dudnichenko (8) Néstor Llinás-Quintero (9) Shigehira Saji (10) Yasuo Miyoshi (11) Nadia Harbeck (12) Li Fan (13) Jaime Mejia (13) Vassiliki Karantza (14) David Cescon (15)

(1) Department of Medicine, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, United States;(2) Memorial Sloan Kettering Cancer Center, NY, United States;(3) Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Republic of Korea;(4) Oncopole Claudius-Regaud, IUCT, France;(5) Oncology Unit, Department of Internal Medicine, School of Medicine, Universidad de la Frontera, Chile;(6) Samsung Medical Center, Republic of Korea;(7) Medical Center Verum, Ukraine;(8) V.T.Zaitsev Institute of General and Urgent Surgery of Academy of Medical Sciences of Ukraine, Tumors of Visceral Organs and Soft Tissues, Ukraine;(9) Clinical Oncology Group, Fundación Colombiana de Cancerología-Clinica Vida, Colombia;(10) Fukushima Medical University Hospital, Japan;(11) Dept of Surgery, Division of Breast and Endocrine Surgery, Hyogo Medical University, Nishinomiya-hama, Hyogo, Japan;(12) University of Munich, Germany;(13) Merck & Co., Inc., Rahway, NJ, United States;(14) Merck Sharp & Dohme LLC, Rahway, NJ, United States;(15) Princess Margaret Cancer Centre/UHN, Toronto, Ontario, Canada.

GS01-06 Advancing Evidence of the Associations Between Specific Benign Breast Diagnoses and Future Breast Cancer Risk. Olivia Sattayapiwat (1) Karla Kerlikowske (2) Donald Weaver (3) Alexander Borowsky (4) Theresa Keegan (5) Brian Sprague (3) Diana Miglioretti (5)

(1) University of California at Davis, Davis, California, United States;(2) University of California, San Francisco;(3) University of Vermont;(4) UC Davis, Sacramento, CA, United States;(5) University of California at Davis.

GS01-08 CDK4/6 inhibition is a potential vulnerability in NF1-depleted ER+ breast cancer. Ze-Yi Zheng (1) Anran Chen (1) Eric Jaehnig (2) Meenakshi Anurag (1) Jonathan Lei (1) Chenwei Wang (1) Long Feng (1) Purba Singh (1) Hilda Kennedy (1) Jin Cao (3) Ghazal Yadav (4) Jill Tsai (5) Xi Chen (1) Charles Foulds (1) Bora Lim (2) Matthew Ellis (6) Bing Zhang (1) Eric Chang (7)

(1) Baylor College of Medicine;(2) Baylor College of Medicine, Houston, TX, United States;(3) Zhejiang University;(4) Texas A&M University;(5) Guardant;(6) AstraZeneca;(7) Lester Sue Smith Breast Center, Baylor College of Medicine, Houston, Texas, United States.

GS01-10 HER2CLIMB-02: Randomized, Double-Blind Phase 3 Trial of Tucatinib and Trastuzumab Emtansine for Previously Treated HER2-Positive Metastatic Breast Cancer. Sara Hurvitz (1) Sherene Loi (2) Joyce O'Shaughnessy (3) Alicia Okines (4) Sara Tolaney (5) Joo Hyuk Sohn (6) Cristina Saura (7) Xiaofu Zhu (8) David Cameron (9) Thomas Bachelot (10) Erika Hamilton (11) Giuseppe Curigliano (12) Antonio Wolff (13) Nadia Harbeck (14) Norikazu Masuda (15) Linda Vahdat (16) Khalil Zaman (17) Frances Valdes-Albini (18) Margaret Block (19) Timothy Pluard (20) Tira Tan (21) Chelsea Gawryletz (22) Arlene Chan (23) Philippe Bedard (24) Rinat Yerushalmi (25) Binghe Xu (26) Konstantinos Tryfonidis (27) Michael Schmitt (28) Joan Xie (28) Virginia Borges (29)

(1) Fred Hutchinson Cancer Center/University of Washington, Los Angeles, CA, United States;(2) Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia;(3) Baylor University Medical Center, Texas Oncology, US Oncology, Dallas, TX, United States;(4) The Royal Marsden NHS Foundation Trust, London, England, United Kingdom;(5) Dana-Farber Cancer Institute, Boston, MA, United States;(6) Yonsei Cancer Center, Republic of Korea;(7) Vall d'Hebron Institute of Oncology (VHIO), Vall d'Hebron University

Hospital, Barcelona, Catalonia, Spain;(8) University of Alberta / Cross Cancer Institute, Edmonton, Alberta, Canada;(9) Institute of Genetics and Cancer, University of Edinburgh, United Kingdom;(10) Medical Oncology, Centre Léon Bérard, France;(11) Sarah Cannon Research Institute / Tennessee Oncology-Nashville, Nashville, TN, United States;(12) European Institute of Oncology and University of Milano, Milano, Lombardia, Italy;(13) Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, United States;(14) University of Munich, Germany;(15) Nagoya University Graduate School of Medicine, Department of Surgery, Breast Oncology NHO Osaka National Hospital;(16) Dartmouth Health, Lebanon, NH, United States;(17) Breast Center, Lausanne University Hospital CHUV, Switzerland;(18) University of Miami;(19) Nebraska Cancer Specialists, Omaha, NE, United States;(20) Saint Luke's Cancer Institute, University of Missouri, Kansas City, MO, United States;(21) National Cancer Centre Singapore, Singapore;(22) UHealth, Fort Collins, CO, United States;(23) Breast Cancer Research Centre – Western Australia, Hollywood Consulting Centre, WA 6009, Nedlands, Western Australia, Australia;(24) Princess Margaret Cancer Centre, Toronto, Ontario, Canada;(25) Rabin Medical Center-Beilinson Campus, Israel;(26) Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, China;(27) Merck & Co., Inc., Rahway, NJ, United States;(28) Seagen Inc., Bothell, WA, United States;(29) University of Colorado Cancer Center, CO, United States.

GENERAL SESSION 2 | THURSDAY, DECEMBER 7 | 8:15AM-11:15AM CT

GS02-01 Randomised phase 3 study of datopotamab deruxtecan vs chemotherapy for patients with inoperable or metastatic hormone receptor-positive, HER2- breast cancer: efficacy, safety and biomarker results from TROPION-Breast01. Aditya Bardia (1) Komal Jhaveri (2) Seock-Ah Im (3) Michelino De Laurentiis (4) Binghe Xu (5) Sonia Pernas (6) Giuliano Borges (7) David Cescon (8) Masaya Hattori (9) Yen-Shen Lu (10) Noelia Martínez-Jáñez (11) Erika Hamilton (12) Shusen Wang (13) Junji Tsurutani (14) Kevin Kalinsky (15) Lu Xu (16) Sabrina Khan (17) Neelima Denduluri (17) Hope Rugo (18) Barbara Pistilli (19)

(1) Massachusetts General Hospital Cancer Center, Boston, MA, United States;(2) Memorial Sloan Kettering Cancer Center, New York, NY, United States;(3) Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Republic of Korea;(4) Istituto Nazionale dei Tumori IRCCS 'Fondazione Pascale, Italy;(5) Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, China;(6) SOLTI Cancer Research Group, Barcelona, Spain Institut Catala d'Oncologia; IDIBELL, L'Hospitalet, Spain;(7) Tapirama, Brazil;(8) Princess Margaret Cancer Centre/UHN, Toronto, Ontario, Canada;(9) Aichi Cancer Center;(10) National Taiwan University Hospital, Taiwan.;(11) Medical Oncology Hospital Universitario Ramón y Cajal. Madrid. Spain. GEICAM Spanish Breast Cancer Group., TRES CANTOS, Madrid, Spain;(12) Sarah Cannon Research Institute / Tennessee Oncology-Nashville, Nashville, TN, United States;(13) Sun yat-sen university cancer center;(14) Advanced Cancer Translational Research Institute at Showa University, Tokyo, Shinagawa, Japan;(15) Winship Cancer Institute at Emory University, Atlanta, GA, United States;(16) AstraZeneca;(17) AstraZeneca, Gaithersburg, MD, United States;(18) Department of Medicine, University of California San Francisco Helen Diller Family Comprehensive Cancer Center, San Francisco, CA, United States;(19) Gustave Roussy, France.

GS02-02 Are nodal ITCs after neoadjuvant chemotherapy an indication for axillary dissection? The OPBC05/EUBREAST-14R/ICARO study. Giacomo Montagna (1) Alison Laws (2) Massimo Ferrucci (3) Mary Mrdutt (1) Natália Polidorio (4) Varadan Sevilimedu (4) Tracy-Ann Moo (5) Andrea Barrio (5) Marissa K. Boyle (6) Flavia Vidal Cabero (7) Daniela Cocco (8) Fabio Corsi (9) Angelena Crown (10) Meghan R. Flanagan (11) Mehmet Ali Gulcelik (12) Callie Hlavin (13) Justyna Jelinska (14) Hasan Karanlik (15) Susan Kesmodel (16) Henry Kuerer (17) Sherko Küemmel (18) Cornelia Leo (19) Tehillah Menes (20) Melissa Pilewskie (21) Nina Pislari (22) Nicola Rocco (23) Jai Min Ryu (24) Leonardo Soares (25) Christoph Tausch (26) M. Umit Ugurlu (27) CICERO URBAN (28) Astrid Botty van de bruele (29) Denise Vorburger (30) Fredrik Wärnberg (31) Anna Weiss (32) Austin Williams (33) Stephanie Wong (34) Steven G. Woodward (35) Susie X. Sun (17) Jennifer Q. Zhang (35) M. Firdos Ziauddin (36) Guldeniz Karadeniz Cakmak (37) Nuran Bese (38) Thorsten Kühn (39) Judy Boughey (40) Tari King (41) Nina Ditsch (42) Maggie Banys-Paluchowski (43) Monica Morrow (5) Walter Weber (44)

(1) Breast Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, United States;(2) Division of Breast Surgery, Department of Surgery, Brigham and Women's Hospital, Harvard Medical School, Breast Oncology Program, Dana-Farber/Brigham and Women's Cancer Center;(3) Padua, Italy;(4) Memorial Sloan Kettering Cancer Center;(5) Memorial Sloan Kettering Cancer Center, New York, NY, United States;(6) Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute, Los Angeles, CA, United States;(7) Santa Paula Hospital, Sao Paulo, SP, Brazil;(8) Valleywise Health Medical Center, Phoenix, AZ, United States;(9) Breast Unit, Department of Surgery, Istituti Clinici Scientifici Maugeri IRCCS, Pavia, Italy; Department of Biomedical and Clinical Sciences "Luigi Sacco", Università di Milano, Italy;(10) True Family Women's Cancer Center, Swedish Cancer Institute;(11) University of Washington / Fred Hutchinson Cancer Center, Seattle, WA, United States;(12)

University of Health Sciences, Gulhane Hospital, Department of Surgery, Turkey;(13) University of Pittsburgh Medical Center, Pittsburgh, PA, United States;(14) Poland;(15) Istanbul University Institute of Oncology, Department of Surgical Oncology, Turkey;(16) University of Miami DeWitt Daughtry Dept. Surgery;(17) The University of Texas MD Anderson Cancer Center, Houston, TX, United States;(18) Breast Unit, Kliniken Essen-Mitte, Germany;(19) Breast Center, Cantonal Hospital Baden, Baden, Switzerland;(20) Sheba Medical Center, Tel Hashomer, Israel; Faculty of Medicine, Tel Aviv University, Israel;(21) University of Michigan, Ann Arbor, MI, United States;(22) Institute of Oncology Ljubljana, Slovenia;(23) Department of Advanced Biomedical Sciences, University Federico II, Italy;(24) Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Gangnam, Ulsangwangyoksi, Republic of Korea;(25) Federal University of Goiás, Brazil;(26) Breast Center Zurich, Switzerland;(27) Marmara University School of Medicine, Department of Surgery, Turkey;(28) Centro de Doenças da Mama- Breast Unit Nossa Senhora das Graças Hospital;(29) Duke University School of Medicine, NC, United States;(30) Breast Cancer Unit, Comprehensive Cancer Center Zurich, University Hospital Zurich, Switzerland;(31) Gothenburg University, Sweden;(32) Division of Surgical Oncology, University of Rochester School of Medicine and Dentistry, Rochester, NY, United States;(33) Fox Chase Cancer Center, Philadelphia, PA, United States;(34) Segal cancer centre, Jewish General Hospital, Lady Davis institute;(35) Department of Surgery, Perelman School of Medicine, The University of Pennsylvania, Philadelphia, PA, United States;(36) Guthrie Cancer Center, Sayre, PA, United States;(37) Zonguldak Bulent Ecevit University, Department of Surgery, Turkey;(38) Research Institute of Senology Acibadem, Istanbul, Turkey;(39) Department of Gynecology, Hospital Esslingen, Germany;(40) Division of Breast and Melanoma Surgical Oncology, Department of Surgery, Mayo Clinic, Rochester, MN, United States;(41) Division of Breast Surgery, Brigham and Women's Hospital, Breast Oncology Program, Dana-Farber/Brigham Cancer Center, Harvard Medical School, Boston, MA, United States;(42) Department of Gynaecology and Obstetrics, University Hospital Augsburg, Germany;(43) Department of Obstetrics and Gynecology, Asklepios Hospital Barmbek, Germany;(44) Breast Center, University Hospital of Basel, Switzerland.

GS02-04 Surgical Treatment of Women with Breast Cancer and a BRCA1 Mutation: An International Analysis of the Impact of Bilateral Mastectomy on Survival. Kelly Metcalfe (1) Jan Lubinski (2) Jana Soukupová (3) Rinat Bernstein-Molho (4) Mina Lee (5) Evans Gareth (6) Arvids Irmejs (7) Robert Fruscio (8) Cynthia Villareal Garza (9) Joanne Ngeow (10) Jennifer Plichta (11) Rinat Yerushalmi (12) Steven Narod (13)

(1) University of Toronto, Toronto, Ontario, Canada;(2) Pomeranian Medical University, Poland;(3) First Faculty of Medicine, Charles University, Czech Republic;(4) Chaim Sheba Medical Center, Israel;(5) Memorial Sloan Kettering Cancer Center;(6) University of Manchester;(7) Riga Stradins University and Pauls Stradins Clinical University Hospital, Latvia;(8) University of Milan Bicocca, Italy;(9) Tecnológico de Monterrey, Mexico;(10) National Cancer Centre Singapore, Singapore;(11) Duke University School of Medicine, Durham, NC, United States;(12) Rabin Medical Center, Israel;(13) Women's College Research Institute, Toronto, Ontario, Canada.

GS02-05 Overview of Axillary Treatment in Early Breast Cancer: patient-level meta-analysis of long-term outcomes among 20,273 women in 29 randomised trials. Gurdeep Mannu (1) Graham Beake (1) Richard Berry (1) David Dodwell (1) Robert Hills (1) Paul McGale (1) Stewart Anderson (2) Ian Campbell (3) Armando E. Giuliano (4) Reshma Jagsi (5) Thorsten Kuehn (6) Rebecca Llewellyn-Bennett (7) Eleftherios Mamounas (8) Robert Mansel (9) Pascal Roy (10) Emiel Rutgers (11) Nisha Sharma (12) Sandra Swain (13) Jonas Bergh (14) On behalf of the EBCTCG (1)

(1) University of Oxford, Oxford, England, United Kingdom;(2) University of Pittsburgh, Pittsburgh, PA, United States;(3) University of Auckland;(4) Cedars-Sinai Medical Center, WEST HOLLYWOOD, CA, United States;(5) Emory University, Ann Arbor, MI, United States;(6) Women's Hospital, Klinikum Esslingen;(7) Southmead Hospital;(8) NSABP Foundation and Orlando Health Cancer Institute, Orlando, FL, USA, Orlando, FL, United States;(9) Cardiff University;(10) Université de Lyon;(11) Department of Surgical Oncology, Netherlands Cancer Institute;(12) Leeds Teaching Hospitals NHS Trust;(13) Georgetown University Medical Center, Lombardi Comprehensive Cancer Center and MedStar Health, Washington, DC, USA;(14) Department of Oncology-Pathology, Karolinska, Institutet, Stockholm, Sweden; Breast Center, Theme Cancer, Karolinska University Hospital, Sweden.

GS02-06 Recurrence-free survival following sentinel node-positive breast cancer without completion axillary lymph node dissection – first results from the international randomized SENOMAC trial. Jana de Boniface (1) Tove Tvedskov (2) Bergkvist Leif (3) Jan Frisell (4) Yvette Andersson (5) Sara Alkner (6) Malin Sund (7) Roger Olofsson Bagge (8) Dan Lundstedt (9) Oreste Davide Gentilini (10) Michalis Kontos (11) Toralf Reimer (12) Birgitte Offersen (13) Thorsten Kühn (14) Lisa Rydén (15) Peer Christiansen (16)

(1) Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden, and Department of Surgery, Capio St. Görans Hospital, Stockholm, Stockholms Lan, Sweden;(2) Herlev-Gentofte Hospital, Hovedstaden, Denmark;(3) Uppsala University;(4) Karolinska Institutet, Sweden;(5) Västmanland Hospital and Uppsala University;(6) Lund University;(7) Umeå University;(8) Department of Surgery, Sahlgrenska University Hospital, Sweden;(9) Gothenburg University, Sweden;(10) Breast Surgery Unit, San Raffaele University Hospital, Italy;(11) 1st Department of Surgery, Laiko Hospital, National and Kapodistrian University of Athens, Greece;(12) University Hospital Rostock, Germany;(13) Aarhus University Hospital;(14) Department of Gynecology, Hospital Esslingen, Germany;(15) Region Skane / Lund University;(16) Aarhus University Hospital, Denmark.

GS02-07 Loco-Regional Irradiation in Patients with Biopsy-proven Axillary Node Involvement at Presentation Who Become Pathologically Node-negative After Neoadjuvant Chemotherapy: Primary Outcomes of NRG Oncology/NSABP B-51/RTOG 1304. Eleftherios Mamounas (1) Hanna Bandos (2) Julia White (3) Thomas Julian (4) Atif Khan (5) Simona Shaitelman (6) Mylin Torres (7) Frank Vicini (8) Patricia Ganz (9) Susan McCloskey (10) Nilendu Gupta (11) X. Allen Li (12) Peter Lucas (13) Nadeem Abu-Rustum (14) Saumil Gandhi (15) Rahul Tendulkar (16) Robert Coleman (17) Keiichi Fujiwara (18) Samantha Seaward (19) William Irvin (20) Kristin Higgins (21) Robert Mutter (22) Jean-Francois Boileau (23) Andrew Muskovitz (24) Reshma Jagsi (25) Anna Weiss (26) Curran, Jr. Walter (27) Norman Wolmark (28)

(1) NSABP Foundation and Orlando Health Cancer Institute, Orlando, FL, USA, Orlando, FL, United States;(2) NRG Oncology Biostatistical Center, University of Pittsburgh, Pittsburgh, PA, United States;(3) Ohio State University, Columbus, OH, United States;(4) Allegheny Health Network Cancer Institute, Pittsburgh, PA, United States;(5) MSKCC;(6) University of Texas MD Anderson Cancer Center;(7) Winship Cancer Institute of Emory University, Atlanta, GA, United States;(8) GenesisCare;(9) UCLA Jonsson Comprehensive Cancer Center, and UCLA Fielding School of Public Health, Los Angeles, CA, United States;(10) Santa Monica UCLA Department of Radiation Oncology;(11) Ohio State University Comprehensive Cancer Center-James Cancer Hospital, Solove Research Institute;(12) Medical College of Wisconsin;(13) UPMC Hillman Cancer Center / NSABP Foundation, Pittsburgh, PA, United States;(14) Memorial Sloan-Kettering Cancer Center LAPS;(15) University of Texas MD Anderson Cancer Center LAPS;(16) CWRU Case Comprehensive Cancer Center LAPS/Tau Taussig Cancer Center, Cleveland Clinic;(17) The US Oncology Network;(18) Saitama Medical University International Medical Center;(19)

Kaiser Permanente NCORP;(20) Bon Secours Saint Francis Medical Center Cancer Institute/Southeast Clinical Oncology Research (SCOR), Midlothian, VA, United States;(21) Emory University - Winship Cancer Institute LAPS;(22) Mayo Clinic LAPS;(23) Jewish General Hospital Segal Cancer Centre, McGill University, Montréal, QC, Canada;(24) William Beaumont Hospital-Royal Oak;(25) Emory University, Ann Arbor, MI, United States;(26) Division of Surgical Oncology, University of Rochester School of Medicine and Dentistry, Rochester, NY, United States;(27) Winship Cancer Institute of Emory University, Atlanta, GA, United States;(28) NSABP Foundation and University of Pittsburgh/UPMC Hillman Cancer Center, Pittsburgh, PA, USA, Pittsburgh, PA, United States.

GS02-08 Five-year outcomes of the IDEA trial of endocrine therapy without radiotherapy after breast-conserving surgery for postmenopausal patients age 50-69 with genomically-selected favorable Stage I breast cancer. Reshma Jaggi (1) Kent Griffith (2) Eleanor Harris (3) Jean Wright (4) Abram Recht (5) Alphonse Taghian (6) Lucille Lee (7) Meena Moran (8) William Small (9) Candice Johnstone (10) Asal Rahimi (11) Gary Freedman (12) Mahvish Muzaffar (13) Bruce Haffty (14) Kathleen Horst (15) Simon Powell (16) Jody Sharp (17) Michael Sabel (18) Anne Schott (19) Mahmoud El-Tamer (20)
(1) Emory University, Ann Arbor, MI, United States;(2) University of Michigan;(3) University Hospitals Case Western Reserve University, Cleveland, OH, United States;(4) Johns Hopkins;(5) Harvard Medical School;(6) Harvard Medical School, Boston, MA, United States;(7) Northwell;(8) Yale;(9) Loyola;(10) Medical College of Wisconsin;(11) University of Texas Southwestern Medical Center, Dallas, TX, United States;(12) University of Pennsylvania;(13) East Carolina University;(14) Rutgers Cancer Institute of New Jersey;(15) Stanford University;(16) MSKCC;(17) University of Michigan;(18) University of Michigan;(19) Rogel Cancer Center, University of Michigan Health, Ann Arbor, MI, United States;(20) Memorial Sloan Kettering Cancer Center, Weill Cornell Medical School, New York, NY, United States.

GS02-10 Effects of a structured and individualized exercise program on fatigue and health-related quality of life in patients with metastatic breast cancer: the multinational randomized controlled PREFERABLE-EFFECT study. Anne May (1) Anouk Hiensch (2) Johanna Depenbusch (3) Martina Schmidt (3) Evelyn Monnikhof (2) Mireia Pelaez (4) Dorothea Clauss (5) Philipp Zimmer (6) Jon Belloso (7) Mark Trevaskis (8) Helene Rundqvist (9) Joachim Wiskemann (10) Jana Muller (10) Carlo Fremd (11) Renske Altena (9) Joanna Kufel-Grabowska (12) Rhode Bijlsma (2) Lobke van Leeuwen-Snoeks (13) Daan ten Bokkel-Huinink (14) Gabe Sonke (15) Bruce Mann (16) Prudence Francis (17) Gary Richardson (18) Isabel Álvarez (19) Wolfram Malter (20) Elsken Van der Wall (21) Neil Aaronson (22) Elżbieta Senkus (23) Ander Urriticoechea (24) Eva Zopf (25) Wilhelm Bloch (5) Martijn Stuiver (22) Yvonne Wengström (9) Karen Steindorf (3)
(1) University Medical Center Utrecht, Utrecht, Not Applicable, Netherlands;(2) University Medical Center Utrecht;(3) German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT) Heidelberg, Germany;(4) OSID-Onkologikoa, Osakidetza;(5) German Sport University Cologne, Germany;(6) German Sport University Cologne and TU Dortmund University, Germany;(7) Onkologikoa;(8) Australian Catholic University;(9) Karolinska Institutet, Sweden;(10) National Center for Tumor Diseases (NCT), Heidelberg University Hospital;(11) Medical Oncology, National Center for Tumor Diseases Heidelberg, NCT (DKFZ and University Hospital), Heidelberg, Baden-Wuerttemberg, Germany;(12) Medical University of Gdańsk;(13) Diakonessenhuis Utrecht;(14) Alexander Monro Hospital;(15) Netherlands Cancer Institute, Netherlands;(16) The Royal Melbourne Hospital, Parkville, Victoria, Australia;(17) Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia;(18) Cabrini;(19) Hospital Universitario Donostia-BioDonostia. GEICAM Spanish Breast Cancer Group., Spain;(20) Universitätsklinikum Köln;(21) University Medical Center Utrecht, Utrecht, Utrecht, Netherlands;(22)

The Netherlands Cancer Institute;(23) Department of Oncology and Radiotherapy, Medical University of Gdańsk, Poland;(24) Oncologikoa;(25) Cabrini Health and Australian Catholic University.

GS02-11 Fertility preservation and assisted reproductive technologies (ART) in breast cancer (BC) patients (pts) interrupting endocrine therapy (ET) to attempt pregnancy. Hatem Azim (1) Samuel Niman (2) Ann Partridge (3) Isabelle Demeestere (4) Monica Ruggeri (5) Marco Colleoni (6) Cristina Saura (7) Chikako Shimizu (8) Anna Saetersdal (9) Judith Kroep (10) Audrey Mailliez (11) Ellen Warner (12) Virginia Borges (13) Frédéric Amant (14) Andrea Gombos (15) Akemi Kataoka (16) Christine Rousset-Jablonski (17) Simona Borstnar (18) Junko Takei (19) Jeong Eon Lee (20) Janice Walshe (21) Manuel Ruíz - Borrego (22) Halle Moore (23) Christobel Saunders (24) Vesna Bjelic-Radicic (25) Snezana Susnjar (26) Fatima Cardoso (27) Natalie Klar (28) Tanya Spanic (29) Kathryn Ruddy (30) Martine Piccart (31) Larissa Korde (32) Aron Goldhirsch (33) Richard Gelber (3) Olivia Pagani (34) Fedro Alessandro Peccatori (35)

(1) School of Medicine, Monterrey Institute of Technology, Monterrey, Nuevo Leon, Mexico;(2) Dana-Farber Cancer Institute;(3) Dana-Farber Cancer Institute, Boston, MA, United States;(4) Research Laboratory on Human Reproduction and Gynecology and Obstetrics Department, Fertility Clinic, HUB-Erasme Hospital, Université Libre de Bruxelles (ULB), Belgium;(5) ETOP IBCSG Partners Foundation, Bern, Bern, Switzerland;(6) Division of Medical Senology, IEO, European Institute of Oncology, IRCCS, Milan, Lombardia, Italy;(7) Vall d'Hebron University Hospital, Vall d'Hebron Institute of Oncology and SOLTI Breast Cancer Research Group, Spain;(8) Department of Breast and Medical Oncology, National Center for Global Health and Medicine, Japan;(9) Oslo University Hospital, Norway;(10) Leiden University Medical Center;(11) Oscar LAMBRET Centre, France;(12) Sunnybrook Odette Cancer Centre, Toronto, Ontario, Canada;(13) University of Colorado Anschutz Medical Campus, Aurora, Colorado, United States;(14) UZ Leuven, Leuven, Vlaams-Brabant, Belgium;(15) Institut Jules Bordet, Belgium;(16) The Cancer Institute Hospital of JFCR, Koto-ku, Tokyo, Japan;(17) Leon Berard Cancer Center, France;(18) Institute of Oncology, Slovenia;(19) Department of Breast Surgical Oncology and Department of Clinical Genetics, St. Luke's international hospital, Chu-o-ku, Tokyo, Japan;(20) Samsung Medical Center, Republic of Korea;(21) Dept. of Medical Oncology St. Vincent's University Hospital and Tallaght University Hospital;(22) Hospital Universitario Virgen del Rocío, Sevilla, Andalucía, Spain;(23) Cleveland Clinic;(24) University of Melbourne;(25) Breast Unit, Helios University Clinic, University Witten/Herdecke, Germany;(26) Institute for Oncology and Radiology of Serbia, Serbia;(27) Breast Unit, Champalimaud Clinical Center/Champalimaud Foundation, Portugal;(28) New York University Langone's Perlmutter Cancer Center, Breast Cancer Center, New York, NY, United States;(29) Europa Donna, The European Breast Cancer Coalition, Slovenia;(30) Mayo Clinic, Rochester, MN, United States;(31) Institut Jules Bordet and l'Université Libre de Bruxelles (U.L.B), Anderlecht, Brussels Hoofdstedelijk Gewest, Belgium;(32) Division of Cancer Treatment and Diagnosis, National Cancer Institute;(33) IEO, European Institute of Oncology;(34) Interdisciplinary Cancer Service Hospital Riviera-Chablais Rennaz; Geneva University Hospitals, Lugano University and Swiss Group for Clinical Cancer Research (SAKK), Switzerland;(35) Fertility and Procreation Unit, IEO European Institute of Oncology IRCCS, Italy.

GENERAL SESSION 3 | FRIDAY, DECEMBER 8 | 8:15AM-11:15AM CT

GS03-01 Magnetic Resonance Imaging and a 12-Gene Expression Assay to Optimize Local Therapy for Ductal Carcinoma In Situ: 5-year clinical outcomes of E4112. Seema Khan (1) Justin Romanoff (2) Constantine Gatsonis (3) Habib Rahbar (4) Ruth Carlos (5) Sunil Badve (6) Jean Wright (7) Constance Lehman (8) Wortia McCaskill-Stevens (9) Ralph Corsetti (10) Derrick Spell (11) Kenneth Blankstein (12) Linda Han (6) Jennifer Sabol (13) John Bumberry (14) Ilana Gareen (15) Bradley Snyder (15) Lynne Wagner (16) Kathy Miller (6) Joseph Sparano (17) Christopher Comstock (18)
(1) Northwestern University, Chicago, Illinois, United States;(2) Brown University - ECOG-ACRIN Biostatistics Center, Providence, RI, United States;(3) Dept of Biostatistics, Brown University School of Public Health;(4) University of Washington;(5) University of Michigan;(6) Indiana University;(7) Johns Hopkins;(8) Massachusetts General Hospital;(9) National Cancer Institute;(10) Ochsner Medical Center;(11) Gulf South NCORP;(12) Hunterdon Medical Center;(13) LMC;(14) Mercy Hospital;(15) Brown University;(16) Wake Forest University School of Medicine;(17) Icahn School of Medicine at Mount Sinai, Tisch Cancer Institute, New York, NY, United States;(18) Memorial Sloan Kettering Cancer Center, New York, NY, United States.

GS03-02 Mammographic surveillance in early breast cancer patients aged 50 years or over: results of the Mammo-50 non-inferiority trial of annual versus less frequent mammography. Janet Dunn (1) Peter Donnelly (2) Nada Elbeltagi (3) Andrea Marshall (4) Alastair Thompson (5) Riccardo Audisio (6) Sarah Pinder (7) David Cameron (8) Amy Campbell (9) Sue Hartup (10) Lesley Turner (11) Annie Young (12) Helen Higgins (13) Eila Watson (14) Sophie Gasson (9) Peter Barrett-Lee (15) Claire Hulme (16) Bethany Shinkins (17) Peter Hall (18) Andy Evans (19)
(1) University of Warwick, Coventry, England, United Kingdom;(2) Torbay and South Devon NHS Foundation Trust;(3) Warwick clinical Trials Unit, University of Warwick, United Kingdom;(4) Warwick Clinical Trials Unit, University of Warwick, Coventry, England, United Kingdom;(5) Baylor College of Medicine, Houston, TX, United States;(6) Department of Surgery, Institute of Clinical Sciences, University of Göteborg, Sweden;(7) School of Cancer and Pharmaceutical Sciences, King's College London Faculty of Life Sciences and Medicine, London, England, United Kingdom;(8) The University of Edinburgh, Edinburgh Cancer Research, EDINBURGH, Scotland, United Kingdom;(9) Warwick Clinical Trials Unit, University of Warwick;(10) Leeds Teaching Hospitals NHS Trust, Leeds, England, United Kingdom;(11) Independent Cancer Patients' Voice;(12) Emerita Professor of Nursing;(13) University of Warwick;(14) Oxford Institute of Applied Health Research, Oxford Brookes University;(15) Velindre University NHS Trust, Cardiff University;(16) University of Exeter Medical School;(17) Warwick Medical School, University of Warwick / Leeds Institute for Health Sciences, University of Leeds;(18) University of Edinburgh, United Kingdom;(19) University of Dundee and NHS Tayside.

GS03-03 Ribociclib (RIB) + nonsteroidal aromatase inhibitor (NSAI) as adjuvant treatment in patients with HR+/HER2- early breast cancer: final invasive disease-free survival (iDFS) analysis from the NATALEE trial. Gabriel Hortobagyi (1) Daniil Stroyakovskiy (2) Denise Yardley (3) Chiun-Shen Huang (4) Peter A. Fasching (5) John Crown (6) Aditya Bardia (7) Stephen Chia (8) Seock-Ah Im (9) Miguel Martín (10) Sherene Loi (11) Binghe Xu (12) Sara Hurvitz (13) Carlos Barrios (14) Michael Untch (15) Rebecca Moroos (16) Frances Visco (17) Federico Parnizari (18) Farhat Ghaznawi (19) Zheng Li (19) Sorcha Waters (20) Arunava Chakravarty (19) Dennis Slamon (21)
(1) The University of Texas MD Anderson Cancer Center, Houston, TX, United States;(2) City Clinical Oncology Hospital 62, Russia;(3) Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN, United States;(4) National Taiwan University Hospital and National Taiwan University College of

Medicine, Taipei, Taiwan, Taipei, United States;(5) Department of Obstetrics and Gynecology, University Hospital Erlangen, Germany;(6) St Vincent's University Hospital, Dublin 4, Dublin, Ireland;(7) Massachusetts General Hospital Cancer Center, Boston, MA, United States;(8) British Columbia Cancer Agency, Vancouver, British Columbia, Canada;(9) Seoul National University Hospital, Cancer Research Institute, Seoul National University College of Medicine, Republic of Korea;(10) Hospital General Universitario Gregorio Marañón, Spain;(11) Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia;(12) Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, China;(13) Fred Hutchinson Cancer Center/University of Washington, Los Angeles, CA, United States;(14) Latin American Cooperative Oncology Group - LACOG, Porto Alegre, Rio Grande do Sul, Brazil;(15) AGO-B and HELIOS Klinikum Berlin Buch, Berlin, Germany;(16) UF Health Cancer Center – Orlando Health, Orlando, FL, United States;(17) National Breast Cancer Coalition (NBCC), Washington DC, District of Columbia, United States;(18) TRIO - Translational Research in Oncology, Uruguay;(19) Novartis Pharmaceuticals Corporation, East Hanover, NJ, United States;(20) Novartis Ireland, Ireland;(21) UCLA David Geffen School of Medicine, Los Angeles, CA, United States.

GS03-04 Novel Mechanisms of CDH1 Inactivation in Breast Invasive Lobular Carcinoma Unveiled by the Integration of Artificial Intelligence and Genomics.

Fresia Pareja (1) Higinio Dopeso (2) Yikan Wang (3) Andrea Gazzo (2) David Brown (4) Pier Selenica (5) Jan Bernhard (6) Fatemeh Derakhshan (2) Edaise M. da Silva (2) Lorraine Colon-Cartagena (7) Thais Basili (2) Antonio Marra (8) Jillian Sue (6) Qiqi Ye (2) Arnaud Da Cruz Paula (9) Selma Yeni (4) Xin Pei (10) Hunter Green (4) Kaitlyn Gill (4) Yingjie Zhu (2) Matthew Lee (6) Ran Godrich (6) Adam Casson (6) Britta Weigelt (2) Nadeem Riaz (10) Hanna Y Wen (5) Edi Brogi (5) Matthew Hanna (4) Diana Mandelker (4) Jeremy Kunz (6) Brandon Rothrock (6) Sarat Chandarlapaty (11) Christopher Kanan (12) Gerard Oakley III (3) David Klimstra (13) Thomas Fuchs (6) Jorge Reis-Filho (14)

(1) Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, United States;(2) Memorial Sloan Kettering Cancer Center, New York, NY, United States;(3) Paige;(4) Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center;(5) Memorial Sloan Kettering Cancer Center;(6) Paige AI;(7) Department of Pathology, Yale School of Medicine;(8) IEO Istituto Europeo di Oncologia;(9) Department of Surgery, Memorial Sloan Kettering Cancer Center;(10) Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center;(11) Memorial Sloan Cancer Center, New York, NY, United States;(12) University of Rochester, Rochester, NY, United States;(13) Paige, Middletown, NY, United States;(14) AstraZeneca, Gaithersburg, MD, United States.

GS03-06 Genomic and transcriptomic profiling of primary tumors from patients with HR+, HER2-, node-positive, high-risk early breast cancer in the monarchE trial.

Nicholas Turner (1) Jorge Reis-Filho (2) Matthew Goetz (3) Christine Desmedt (4) Sarat Chandarlapaty (5) Hironobu Sasano (6) Carlos Arteaga (7) Sherene Loi (8) Stephanie Graff (9) Deli Liu (10) Vanessa Rodrik-Outmezguine (10) Anthony Sireci (10) Cynthia Sandoval Rubenstein (10) Helen Won (10) Lacey M. Litchfield (10) Maria Munoz (11) Stephen Johnston (12)

(1) Royal Marsden Hospital, Institute of Cancer Research, London, England, United Kingdom;(2) AstraZeneca, Gaithersburg, MD, United States;(3) Mayo Clinic, Rochester, MN, United States;(4) Laboratory for Translation Breast Cancer Research/KU Leuven, Leuven, Vlaams-Brabant, Belgium;(5) Memorial Sloan Cancer Center, New York, NY, United States;(6) Department of Pathology, Tohoku University Hospital, Japan;(7) UT Southwestern Medical Center, Simmons Comprehensive Cancer Center, Dallas, TX, United States;(8) Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia;(9) Legorreta Cancer Center at Brown University, Lifespan Cancer Institute, Providence, RI, United

States;(10) Eli Lilly and Company, Indianapolis, IN, United States;(11) Eli Lilly and Company;(12) The Royal Marsden Hospital, United Kingdom.

GS03-07 Protocol-defined biomarker analysis in the PALLAS (AFT-05) adjuvant trial: Genomic subtype derived from RNA sequencing of HR+/HER2- early breast cancer.. Daniel Stover (1) Dominik Hlauschek (2) Erica Mayer (3) W. Fraser Symmans (4) Mark Watson (5) Iros Barozzi (6) Martin Filipits (7) Karla Ballman (8) Meritxell Bellet- Ezquerro (9) Justin Balko (10) Gabor Rubovszky (11) Nicholas Zdenkowski (12) Adam Brufsky (13) Guenther Steger (14) Claudine Isaacs (15) Sibylle Loibl (16) Fernando Henao (17) Meredith Regan (3) Yuan Liu (18) Christian Fesl (2) Patrick O'Brien (8) Angela DeMichele (19) Michael Gnant (20) Otto Metzger (3)

(1) Ohio State University Comprehensive Cancer Center, Columbus, OH, United States;(2) Austrian Breast Cancer and Colorectal Study Group, Austria;(3) Dana-Farber Cancer Institute, Boston, MA, United States;(4) UT MD Anderson Cancer Center;(5) Washington University School of Medicine;(6) Medical University of Vienna;(7) Center for Cancer Research, Medical University of Vienna, Austria;(8) Mayo Clinic;(9) Vall d'Hebron Institute of Oncology (VHIO), Barcelona, Spain; Medical Oncology Department, Vall d'Hebron University Hospital, Spain;(10) Vanderbilt University Medical Center, Nashville, TN, United States;(11) National Institute of Oncology, Hungary;(12) Breast Cancer Trials;(13) UPMC Hillman Cancer Center, University of Pittsburgh Medical Center;(14) Department of Internal Medicine I, Medical University of Vienna, Vienna, Austria, Austria;(15) Georgetown University;(16) German Breast Group, Neu-Isenburg, Germany; Centre for Haematology and Oncology Bethanien, Frankfurt, Germany, Germany;(17) Medical Oncology Hospital Virgen de la Macarena;(18) Pfizer Inc, San Diego, CA, United States;(19) University of Pennsylvania, Philadelphia, PA, United States;(20) Medical University of Vienna, Austria.

GS03-09 Characterization and proposed therapeutic exploitation of fusion RNAs in metastatic breast cancers. Nolan Priedigkeit (1) Alinés Lebrón-Torres (2) Janny Liao (3) Jean-Baptiste Alberge (4) Stefania Morganti (5) Jakob Weiss (1) Jorge Gomez Tejeda Zanudo (4) Albert Grinshpun (6) Melissa Hughes (7) Karla Helvie (4) Kerry Sendrick (4) Kyleen Nguyen (7) Sarah Strauss (4) Janet Files (4) Maxwell Lloyd (8) Nikhil Wagle (4) Chip Stewart (9) Eric Winer (10) Bruce Johnson (11) Yvonne Li (12) Rinath Jeselsohn (13) Sara Tolaney (13) Daniel Abravanel (4) Nancy Lin (14) Heather Parsons (15) Gad Getz (16) Steffi Oesterreich (17) ADRIAN LEE (18) Todd Golub (16)

(1) Dana-Farber Cancer Institute / Broad Institute of MIT and Harvard;(2) Broad Institute of MIT and Harvard / Davidson College;(3) Broad Institute of MIT and Harvard / Harvard College;(4) Dana-Farber Cancer Institute;(5) Dana-Farber Cancer Institute; Harvard Medical School; Broad Institute of MIT and Harvard;(6) Dana-Farber Cancer Institute, and Harvard Medical School;(7) Dana Farber Cancer Institute;(8) Beth Israel Deaconess Medical Center;(9) Broad Institute of MIT and Harvard;(10) Yale Cancer Center, New Haven, CT, United States;(11) Medical Oncology, Dana-Farber Cancer Institute; Harvard Medical School;(12) Medical Oncology, Dana-Farber Cancer Institute;(13) Dana-Farber Cancer Institute, Boston, MA, United States;(14) Dana-Farber Cancer Institute, and Harvard Medical School, Boston, MA, United States;(15) Dana Farber Cancer Institute; Harvard Medical School, Boston, MA, United States;(16) Harvard Medical School / Broad Institute of MIT and Harvard;(17) University of Pittsburgh, Pittsburgh, PA, United States;(18) UPMC Hillman Cancer Center, Pittsburgh, PA, United States.

GS03-10 Allosteric PI3K-alpha inhibition overcomes on-target resistance to orthosteric inhibitors mediated by secondary PIK3CA mutations. Andreas Varkaris (1) Ferran Fec de la Cruz (2) Elizabeth Martin (3) Bryanna Nordern (2) Nicholas Chevalier (4) Ignaty Leshchiner (5) Anastasia Stavridi (6)

Janice Kim (7) Alkistis Papatheodoridi (8) Hakan Gunaydin (9) Brian Danysh (10) Laxmi Parida (11) Ioannis Sanidas (4) Yongli Ji (12) Kayao Lau (2) Gerburg Wulf (13) Aditya Bardia (14) Laura Spring (14) Steven Isakoff (15) Jochen Lennerz (4) Levi Pierce (9) Ermira Pazolli (9) Gad Getz (16) Ryan Corcoran (2) Dejan Juric (17)

(1) Massachusetts General Hospital, Boston, Massachusetts, United States;(2) Massachusetts General Cancer Center;(3) Broad Institute of MIT;(4) Mass General Cancer Center;(5) Boston University;(6) Beth Israel Deaconess Medical Center;(7) Massachusetts General Hospital, Boston, MA, United States;(8) Department of Therapeutics, University of Athens;(9) Relay Therapeutics;(10) Broad institute of MIT;(11) IBM;(12) Emerson Hospital;(13) Harvard Medical School;(14) Massachusetts General Hospital Cancer Center, Boston, MA, United States;(15) Cancer Center, Massachusetts General Hospital;(16) Broad Institute of MIT, Mass General Cancer Center;(17) Massachusetts General Hospital Cancer Center, Department of Medicine, Harvard Medical School, Boston, MA, United States.

GS03-11 Germline-mediated immunoediting sculpts breast cancer subtypes and metastatic proclivity.
Kathleen Houlahan (1) Aziz Khan (2) Noah Greenwald (2) Robert West (3) Michael Angelo (2) Christina Curtis (4)

(1) Stanford University, CA, United States;(2) Stanford;(3) Stanford University Medical Center, Stanford, CA, United States;(4) Stanford University, Stanford, CA, United States.